Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) had its target price raised by Jefferies Group LLC from $13.00 to $18.00 in a research note published on Monday. The brokerage currently has a buy rating on the biotechnology company’s stock. Jefferies Group also issued estimates for Spectrum Pharmaceuticals’ Q3 2017 earnings at ($0.19) EPS, Q4 2017 earnings at ($0.22) EPS, FY2017 earnings at ($0.96) EPS, FY2018 earnings at ($0.76) EPS, FY2020 earnings at $0.28 EPS and FY2021 earnings at $1.16 EPS.
Several other research firms have also recently commented on SPPI. Zacks Investment Research upgraded Spectrum Pharmaceuticals from a hold rating to a buy rating and set a $10.00 price target for the company in a report on Wednesday, August 9th. HC Wainwright restated a buy rating and issued a $14.00 price target on shares of Spectrum Pharmaceuticals in a report on Thursday, September 14th. ValuEngine upgraded Spectrum Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, August 17th. Finally, BidaskClub cut Spectrum Pharmaceuticals from a strong-buy rating to a buy rating in a report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. Spectrum Pharmaceuticals currently has a consensus rating of Buy and an average price target of $14.75.
Spectrum Pharmaceuticals (SPPI) opened at 13.67 on Monday. The firm has a 50-day moving average of $11.15 and a 200-day moving average of $8.13. Spectrum Pharmaceuticals has a 52-week low of $3.21 and a 52-week high of $15.32. The firm’s market cap is $1.07 billion.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01. The firm had revenue of $34.30 million during the quarter, compared to analysts’ expectations of $30.50 million. Spectrum Pharmaceuticals had a negative return on equity of 30.95% and a negative net margin of 59.33%. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.35) EPS. Equities analysts anticipate that Spectrum Pharmaceuticals will post ($1.06) EPS for the current year.
WARNING: This report was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.com-unik.info/2017/10/12/spectrum-pharmaceuticals-inc-sppi-price-target-raised-to-18-00.html.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Spectrum Pharmaceuticals by 1.2% in the 2nd quarter. Vanguard Group Inc. now owns 7,292,704 shares of the biotechnology company’s stock valued at $54,331,000 after buying an additional 83,981 shares during the period. Renaissance Technologies LLC grew its holdings in Spectrum Pharmaceuticals by 6.9% in the 2nd quarter. Renaissance Technologies LLC now owns 6,071,817 shares of the biotechnology company’s stock valued at $45,235,000 after buying an additional 392,017 shares during the period. State Street Corp grew its holdings in Spectrum Pharmaceuticals by 28.3% in the 2nd quarter. State Street Corp now owns 3,020,563 shares of the biotechnology company’s stock valued at $22,507,000 after buying an additional 666,605 shares during the period. Dimensional Fund Advisors LP grew its holdings in Spectrum Pharmaceuticals by 21.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,674,679 shares of the biotechnology company’s stock valued at $19,926,000 after buying an additional 463,434 shares during the period. Finally, Macquarie Group Ltd. grew its holdings in Spectrum Pharmaceuticals by 9.4% in the 2nd quarter. Macquarie Group Ltd. now owns 2,247,493 shares of the biotechnology company’s stock valued at $16,744,000 after buying an additional 193,883 shares during the period. Institutional investors own 66.09% of the company’s stock.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
What are top analysts saying about Spectrum Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Spectrum Pharmaceuticals Inc. and related companies.